SCHEMBL14897250

SCHEMBL14897250

COc1ccc(NC(=O)c2c(C)nc3ccc(-c4ccccc4C)nn23)nn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.37
▸ RAB9A P51151 4/20 0.37
▸ SMN1; SMN2 Q16637 4/20 0.37
▸ MAPT P10636 4/20 0.37
▸ TP53 P04637 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ POLB P06746 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ SMYD2 Q9NRG4 1/20 0.36
▸ TGFBR1 P36897 2/20 0.35
▸ CSNK1D P48730 1/20 0.35
▸ CSNK1E P49674 1/20 0.35
▸ KMT2A Q03164 1/20 0.34
▸ PDE2A O00408 1/20 0.34
▸ PDE6D O43924 1/20 0.34
▸ PDE6A P16499 1/20 0.34
▸ PDE6G P18545 1/20 0.34
▸ PDE6B P35913 1/20 0.34
▸ PDE6C P51160 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14897343 0.91 MAPT (0.36) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL14896912 0.90 EPHB3 (0.39) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL14897329 0.90 MAPT (0.37) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL14896994 0.90 NPC1 (0.38) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL16265183 0.90 NPC1 (0.39) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL14897623 0.88 PDE2A (0.38) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL14896837 0.86 RIPK1 (0.41) MAPTTP53POLBKDM4EPDE2A
SCHEMBL14896998 0.83 FYN (0.40) NPC1RAB9ASMN1; SMN2MAPTPOLB
SCHEMBL16265239 0.82 EPHB3 (0.37) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL14896995 0.82 ADORA2A (0.36) NPC1RAB9ASMN1; SMN2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-2768509-B1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2017-03-22 — — EP disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
WO-2013059587-A9 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2014-10-23 — — WO disclosed
WO-2013059587-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2013-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 NPC1 3941/4885RAB9A 1062/4885SMN1; SMN2 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback